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systolic (58 (19) ml) volumes and LV mass (134 (42) g). CK (median (range)) at 8-12 
hours (620 (74-1344) IU/I) and at the MA scan (228 (57.2508) IUif) correlated with LE 
volume: wO.78, p=O.OOOl and w0.70, p=O.O02, respectively. CK (111 (69-4869) IUif) on 
admission was unrelated to LE volume. CKMB (median (range)) at 8-12 hours (54 (3.4. 
226) mg/ml) and at the MR scan (11 (1.2-406) mg/ml) correlated with LE volume: w0.59, 
p=O.Ol and r=0.58, ~~0.02, respectively. CKMB on admission was unrelated to LE vol. 
ume. 
Conclusions. Plasma concentrations of Tnl measured 8-12 hours after onset of chest 
pain are very closely related to the volume of late enhancement measured by MR sug- 
gesting that the currently recommended timing of Tnl sampling does provide an accurate 
reflection of infarct size. 
1170-101 Homorygote Mutation of Cl61 +T Polymorphism in the 
Exon 6 of Peroxisome Proliferator-Activated Receptor 
$3 Gene Is Associated With Onset of Premature 
Myocardial Infarction 
Tino-Hsrnq Chaq Yi-Heng LI, Jyh-Hong Chen, Hua-Lin Wu, Guey-Yueh Shi, National 
Cheng Kung University Medical Center, Tainan, TaiwanROC 
Background: Peroxisome prokferator-activated receptor (PPAR) is a nuclear receptor. 
Activation of PPAR y with ligands could modulate some gene transcription, thereby lead- 
ing to multiple antiatherogenic and fibrinolybc effects. However, the association between 
effect of Cl61 +T mutation of the exon 6 of PPARTJ and the onset of premature myocar- 
dial infarction IS not clarified. 
Methods: We recruited 146 patients (pts) (mean age 45 yr, 129 male) with premature 
myocardial infarction (Ml) (onset age 5 50 yr) and 146 control subjects (mean age 45.3 
yr, 120 male). Polymerase chain reaction and restrlction fragment length polymorphism 
were used to define ClGl-tT polymorphism. 
Results: The frequency of the PPAR j3 TT genotype among pts with premature Ml was 
significantly higher than that in control subjects (13% vs 5.5% odds ratio [OR] 2.6, 95% 
confidence interval [Cl] 1 .I to 6.1, p=O.O3). This association was not observed in CC, or 
CT genotypes. The homozygote TT genotype (OR 3.1, 95% Cl 1.2 to 7.9) smoking (OR 
3.5, 95% Cl 2.1 to 6.0) hypertension (OR 3.6, 95% Cl 1.9 to 6.9) and diabetes mellitus 
(OR 3.5, 95% Cl 1.5 to 8.4) were independent risk factors for premature Ml after adjust- 
ment of conventional risk factors. 
Conclusion: There was a significant association between the PPAR fl Cl61-1T 
homozygote mutation and the onset of premature Ml in our population. Effect of the TT 
genotype on the production and activity of PPAR ywarrants further investigation. 
1170-102 Reduced Post-Infarction Myocardial Apoptosis in 
Women: A Clue to Their Different Clinical Course? 
Giuseppe G. Biondi-Zoccar, Antonio Abbate, Rossana Bussani. Debora Camilot, Maria- 
Pia Di Manno, Alessandro Petrolini, Luigi M. Biasucci, Alfonso Baldi, Institute of 
Cardiology - Cathokc University of Rome, Rome, Italy 
Background. lschemic heart failure (HF) is less common and severe in women. Myocar- 
dial apoptosis has a fundamental role in post-infarctron remodeling, however, little is 
known about gender-modulation of post-infarction apoptosis. We investigated whether 
apoptosis late after acute myocardial Infarction (AMI) is drfferent in females in compari- 
son to males. 
Methods. Hearts from 21 men and 9 women dying 10 days-2 months after AMI were 
examrned at autopsy. Apoptotic rate (AR) at infarct site and apparently normal myocar- 
dium was assessed with in-situ end labeling for DNA fragmentation (TUNEL) and co- 
staining for caspase-3. We also performed co-stainings for PCNA and SC-35 to identify 
potential false positwe results at TUNEL. Results. AR in infarcted areas was B-fold 
higher in males than in females (21.2% vs 4.3%,p=O.O36). See Figure. This difference 
remained statistically significant even at multivariate analysis (p=O.O20) and was particu- 
larly evident in subjects with persistent infarct-related artery (IRA) occlusion. 
Conclusions. Myocardiocyte apoptosrs after AMI is more severe in men in comparrson 
to women. This difference may explain the more aggressive and progressive course of 
post-infarction HF in men and the relatively more benign LV remodeling in women. 
1170-103 Relation of Growth Hormone and Insulin-Like Growth 
Factor-l to Ventricular Remodeling in Acute Myocardial 
Infarction 
Maria I. Sosa Liprandi, Alvaro Sosa Liprandi, Victor D. Dar& Sergio Baratta. Miguel A. 
Gonzalez, Ricardo M. Iglesias, Carlos D. Pellegrinr, Ana Keselman, Eliseo Gonzalez, 
Sanatorio Mitre, Buenos Aires, Argentina 
Background Experimental data have suggested that early treatment with growth hor- 
mone (GH) and insulin-like growth factor-l(IGF-1) could attenuate ventricular remodeling 
after acute myocardial infarction. Our aim was to determine whether serum GH and IGF- 
1 level are related to ventricular remodeling in patients with acute myocardial infarction. 
Methods: Within 24 hours of chest pain onset, 52 consecutive patients were studied at 
baseline, on day 5, and at 6 weeks after the acute myocardial infarction. GH and IGF-1 
were measured and related to positive ventricular remodeling defined as an increase 
25% in left ventricular diastolic volume (LVDV), left ventricular systolic volume (LVSV). 
their variations (A EDV and A ESV) and ejection fraction (EF) evaluated by echocardio- 
graphy (Sympson’s method) on day 3 and 6 weeks. 
Results: Median value of GH was higher at baseline (2.19 ng/ml) and significantly 
decreased at day 5 (0.26 ng/ml) and 6 weeks (0.55 @ml) (p<O.oOl). IGF-1 significantly 
increased from baseline: mean 136i90 ng/ml, to day 5: mean164395 ng/ml and 6 weeks: 
mean ZOO&9 rig/ml, p< 0.0001). Patients with baseline IGF-1 below the median value 
showed less EF at 6 weeks than patients above the median: 46*11% versus 53r9.8% 
respectively (p=O.Ol), and significant increase ESV: AESV 9+18 versus AESV 2rl5 
(p=O.OZ). At day 5, IGF-1 below the median value was associated with a significant 
increase ESV: AESV 11.35+14 versus AESV 0.1 I+18 (p=O.O4). 
Patients with positive ventricular remodekng showed significant lower levels of IGF- 
1(117+84nglml) than those with negative remodeling (165*93ng/ml) (p=O.O5) at base- 
line, and day 5 (152+11 lng/ml versus 183*6lng/ml respectively) (p=O.O3). No significant 
differences were found at 6 weeks. No association was found between GH levels, ven- 
tricular remodeling and ejection fraction at baseline, day 5 and 6 weeks. 
Conclusions: There was a strong association of low serum levels of IGF-1 with left ven- 
tricular remodeling and impaired ventncular function at baseline and day 5. No relation 
was found with GH, a labtle and unstable biological marker. This results could suggest a 
protective role of IGF-1 to prevent the early remodeling process after myocardial infarc- 
tion. 
1170-104 ST Elevation Myocardial Infarction Caused by 
Spontaneous Distal Embolization From Unstable 
Lesions: Frequency and Sequelae of a Distinct 
Pathophysiological Entity 
Jose P. Henriques Felix Zijlstra, the Zwolle Myocardial Infarction Study Group, lsala 
Klinieken, Locatie Weezenlanden, Zwolle, The Netherlands 
Background: Distal embolization is an important feature in acute myocardial infarction. 
Previously, we demonstrated that distal embolization after primary angioplasty resulted 
in larger infarct size. However, distal embolization may in part be due to angroplasty. 
Therefore, we investigated the characteristics of patients with distal embolization before 
primary angioplasty. 
Methods: We assessed angiographic data of 631 patients. Distal embolization before 
angioplasty was defined as a distal filling defect with an abrupt ‘cut-of? in at least one of 
the peripheral coronary branches of the infarct related artery, distal to the infarct related 
segment. Follow-up was obtained at 30 days. 
Results: Distal embolization before angroplasty was visible in 30 (5%) patients. They 
were younger than patients without distal embolrzation (56~ vs. 6ly, p=O.O4). Patients 
with distal embolization before angroplasty had a higher rate of TIMI 2 or 3 flow before 
angioplasty (57% vs. 31%, p=O.O05), more often thrombus (53% vs.12%. pl (20% vs. 
7%, ~~0.03) and had a hrgher 30 day modality rate (10% vs. 2%. p=O.O3). 
Conclusions: Distal embolization before angioplasty can be visualized in 5% of the 
patients with acute myocardial infarction. It is associated with more thrombus, a lower 
angioplasty success rate and heralds a higher rate of intracoronary stenting. It is associ- 
ated with more Killip class>1 and higher 30 days mortality Patients with distal emboliza- 
tion before angioplasty are a distinct subset of patients with a high rate of complicated 
myocardial infarction. 
1170-105 Marked Reduction in No-Reflow With Late Initiation of 
Hypothermia in a Rabbit Myocardial Infarct Model 
Sharon L. Hale, Michael W. Dae, Robed A. Kloner. Good Samaritan Hospital, Los 
Angeles, CA, University of Southern California, Los Angeles, CA 
Background: Hypothermia rn conjunction with reperfusion (rep) is a novel approach for 
treatment of acute myocardlal infarction now being tried in humans. Whether reflow, an 
important predictor of clinical outcome, is changed when hypothermia is initiated late dur- 
ing ischemia is unknown. This study tests if myocardial hypothermia, starting near the 
end of ischemia and continuing for 2 hr of rep. protects microvasculature reducing no- 
reflow. Methods: Rabbit hearts recewed 30 min coronary artery occlusion/ 3 h rep. 
Regional hypothermia (H, n=lO) started 10 min before rep and continued for 2 hr of rep 
was compared with normothermia (N. n=lO). Regional myocardial blood flow (micro- 
spheres) was measured during occlusion and at the end of rep. The anatomic zone of 
no-reflow (thioflavin S in viva injection) and zone of macroscopic hemorrhage were mea- 
sured in the LV. Results: Myocardial temperature (” C) in H was decreased by 5.OkO.4 
from baseline (36.9-0.2) and remained about 32” during the cooling phase, returning to 
36.3+0.3 at 3 hr. N hearts remained within 0.2” of baseline (37.4+0.1) throughout. Both 
groups were equally ischemic during occlusion, but at the end of rep reflow to the prew- 
ously rschemic zone was significantly higher in H, 69+6% of normal blood flow vs 34*5% 
in N (p=.OOOl). The zone of anatomic no-reflow was significantly smaller in H, 12+4% of 
the ischemic zone vs 37*3% in N (p=.OOOl), and the macroscopic zone of hemorrhage 
382A ABSTRACTS - Myocardial Ischemia and Infarction JACC March 19,2003 
was signiflcsntly smaller I” H vs N hearts (14+4% and 45+4%, p=.OOOO). Conclusion: with Killip Class II or Ill. The Table shows the medications administered during the first 24 
This study shows that hypothermic therapy initiated late during ischemia and continuing hours of presentation and at discharge. 
for several hours of rep significantly improves reflow and reduces macroscopic zones of Conclusion: Despite available data showing the benefit of proven medical therapies for 
no-reflow and hemorrhage in this model, suggesting protection of the microvasculature the treatment of patients with acute coronary syndromes and congestive head failure, 
by reducing repeiiusion injury. As reflow is a predictor of outcome, this intervention may except for aspirin, many of these medications continue to be underutilized especially in 
have important clinical implications. high-risk patients. 
POSTER SESSION 
Medication Use at 
Randomization 
Medication Use at 
Discharge 
Killip I 
(8558) 
Killip 111111 P Killip I 
(861) value (8360) 
Killip II/ 
Ill 
(778) 
372 
(48%) 
653 
(84%) 
405 
(52%) 
220 
(28%) 
152 
(20%) 
502 
(65%) 
165 
(21%) 
P 
1171 Refining Treatment Strategies Among 
Patients With Acute Coronary Syndromes 
Tuesday, April 01, 2003, Noon-2:00 p.m. 
McCormick Place, Hall A 
Presentation Hour: Noon-l :00 p.m. 
1171-106 Early Short-Term Use of Atorvastatin and Pravastatin in 
Patients With Non-ST Elevation Acute Coronary 
Syndrome: Changes of Hemostatic Parameters 
Ekaterlna Pokrovskaya, Nikolai Vaulln, Oleg Averkov. Natalia Slavina. Nikolai 
Gratsiansky. Institute of Physico-Chemical Medicine, Moskva, Russian Federation 
Background. Whether statins rapidly (in 1-2 weeks) and similarly affect hemostatic 
parameters in patients with non-ST elevation acute coronary syndrome (NSTEACS) is 
unknown. 
Methods: Ninety aspirin and heparin treated patients with NSTEACS were randomized 
~24 hours from pain onset to open pravastatin 40 mglday (n=31), atorvastatin 10 mgiday 
(n=30) or atorvastatin 40 mglday (n=29). Plasma thrombin-antithrombin complex (TAT), 
prothrombin fragments I+2 (Fl+2). D-dimer and van Willebrand factor (vWF) were mea- 
sured by ELISA at baseline, on days 7, 14. Results were compared with data from con- 
trols (n=l8) of another randomized study on similarly treated patients. 
Results: In all treatment groups levels of low-density lipoprotein cholesterol (LDLC) were 
lowered by days 7 (pcO,Ol) and 14 (p<O,Ol vs. baseline and for both atolvastatin groups 
vs. day 7). In pravastatin group levels of TAT and Fl+2 decreased, while vWF level 
increased (table). In atorvastatin groups levels of TAT and F 1+2 increased while level of 
vWF decreased Contrary to pravastatin group changes in atorvastatin groups more 
resembled those in controls not receiving lipid lowering drugs. There was slight negative 
correlation between changes of LDLC and TAT levels. No consistent changes of D-dimer 
occurred. 
Conclusion : Early use of pravastatin and atorvastatin in patients with NSTEACS was 
associated with divergent changes of some hemostatic paramebxs. 
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1171-108 Superior Efficacy of Low Molecular Weight Heparin 
Versus Unfractionated Heparin in Acute Coronary 
Syndromes Without ST Elevation 
Thlbaud Dam& Anissa Bouzamondo, Gilles Montalescot, Philippe Lechat, Pitie 
Saleptriere Hospital, Pans, France 
Background: In acute coronary syndrome without ST elevation (ACS), there is conflict- 
ing evidence regarding the efficacy of low molecular weight heparin (LMWH) versus 
unfractionnated heparin (UFH). We performed a meta-analysis of trials comparing the 
class of LMWH versus UFH on the combined criteria of Death or Myocardial Infarction (D 
or MI) I” ACS. 
Methods: Randomised trials were identified using Medline and Cochrane database. 
Pooled Relative Risk was calculated with published data. Seven trials Including 15998 
patients fulfilled the inclusion criteria (Gudinkel, FRIC, FRISC, FRISC II, ESSENCE, TIMI 
11 B, FRAXIS). 
Results: M&a-analysis of five trials (Gurfinkel, FRIC. ESSENCE, TIMI llB, FRAXIS), 
including 12169 patients demonstrated superiority of LMWH versus UFH to reduce D or 
Ml during the acute phase (6-8days) [RR=0.83; 95%Cl(O.70-0.99); p=O.O42]. Heteroge- 
neity test was non significant (p=O.47) but subgroup analysis according lo the type of 
LMWH, showed that amplitute of benefit was highest with enoxaparin IRRz0.78; (0.62. 
0.96); p=O.O2] compared to dalteparin [R&1.09; (0.65.1.82)] or nadroparin (RRz0.92; 
(0.62-1.37)]. M&-analysis of long term LMWH administration trials (FRIC, FRISC, 
FRISCII, TIMIllB, FRAXIS) showed that no additional benefit [RR=O.SE; (0.82-1.16); 
p=O.78] was obtained when considering only events occurring after the acute phase. 
During the acute phase, no significant difference was observed for major bleedings 
[RR=l.Ol; (0.81.1.26)]. However minor bleedings were significantly Increased by LMWH 
[RR=l.96; (1.65.2,61); piO.OOl]. Prolonged administration significantly increased the 
major bleeding rate [RR=2.27; (1.63-3.18); p<O.OOl)]. Conclusion: When considering 
ischemlc events during the first week of ACS, there is a signlflcant favorable class effect 
for LMWH compared to UFH. However, prolonged LMWH treatment increases major 
bleedings without significant additional benefit on ischemic events. 
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1171-107 In-Hospital and Discharge Utilization of Medications in 
Patients With and Without Heart Failure Presenting With 
Acute Coronary Syndromes: Insights From the 
PURSUIT Study 
Monvadi B. Srichai, Robert A. Harrington, Judith S. Hochman, Penny L. Houghtaling, 
Eric J. Velazquez, A. Michael Lincoff, Maarten L. Sirnoons, Wael A. Jaber, The 
Cleveland Clinic Foundation, Cleveland, OH, Duke University Medical Center, Durham, 
NC 
Background: Several medical interventions have been proven in the last two decades to 
improve the prognosis of patients with coronary artery disease and congestive heart fail- 
ure. We evaluated the rate of utilization of proven medical therapies in major national and 
international medical centers participating in the PURSUIT trial. 
Methods: We analyzed 9419 patients who were enrolled in the PURSUIT trial between 
November 1995 and January 1997. We assessed the medication usage at the time of 
randomization and at discharge for patients presenting with and without symptoms of 
hearl failure on presentation. 
Results: 8558 patients presented with Killlp class I and 861 patients were diagnosed 
1171-109 Adherence to Secondary Prevention Therapies 
Following Acute Coronary Syndromes: One-Year 
Results From the Canadian Acute Coronary Syndrome 
Registry 
Andrew T. Yan, Shaun G. Goodman, Mary Tan, David Fitch&t, Chi-Ming Chow, Anatoly 
Langer, Canadian ACS Registry Investigators, University of Toronto and Canadian Heart 
Research Centre. Toronto. ON, Canada 
Background: Clinical trials have clearly established the role of effective pharmacothera- 
pies in the secondary prevention of acute coronary syndrome (ACS) However, there are 
limited data regarding the longer-term adherence to these therapies after discharge. 
Methods: The ACS Registry is a prospective Canadian observational study of 5312 
patients with suspected ACS from 51 centres I” 9 provinces. A final diagnosis of ACS 
was dstermined in 4627 patients (27% Q wave myocardial infarctjon, 31% non-Q myo- 
cardial infarction, 41% unstable angina). Discharge medication use was recorded by 
treating physicians. Follow-up medication use (determlned by standardized telephone 
interview) was available for 3844 one-year survivors (8.8% unavailable). We compared 
the rates of medication use at discharge and at 1 year. 
Results: Medication use in 3844 patients at discharge and at l-year follow-up were as 
follows: 
